Overview

Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes

Status:
Terminated
Trial end date:
2021-01-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if prophylaxis with RTB101 decreases the severity of laboratory-confirmed COVID-19 among adults ≥ 65 years who reside in a nursing homes in which one or more residents or staff have laboratory-confirmed COVID-19
Phase:
Phase 2
Details
Lead Sponsor:
Restorbio Inc.
Treatments:
Dactolisib